Current Edition

Latest Developments in IP Strategies for Pharmaceuticals

The strategies used to create and maintain strong-pharmaceutical patent portfolios must evolve with developments in the pharmaceutical space. These developments include not just scientific advancements but also requirements and practices of regulatory bodies, such as the United States Food and Drug Administration (FDA). This article by Sara A. Leiman, Jordan Gringauz, Stacy Lewis, and Amanda K. Murphy at Finnegan addresses innovative prosecution strategies and usable considerations that may facilitate a better agreement between pharmaceutical patent practice and FDA policy.